Federated Hermes Inc. Buys 192,853 Shares of Insmed Incorporated (NASDAQ:INSM)

Federated Hermes Inc. boosted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 448.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 235,836 shares of the biopharmaceutical company's stock after purchasing an additional 192,853 shares during the quarter. Federated Hermes Inc. owned about 0.13% of Insmed worth $16,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC lifted its holdings in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 163 shares during the period. V Square Quantitative Management LLC boosted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management purchased a new position in Insmed during the 4th quarter valued at about $47,000. Smartleaf Asset Management LLC grew its holdings in Insmed by 98.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 411 shares during the period. Finally, Venturi Wealth Management LLC purchased a new position in shares of Insmed during the fourth quarter valued at approximately $86,000.

Insider Activity at Insmed

In other news, CEO William Lewis sold 31,805 shares of the firm's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $70.18, for a total value of $2,232,074.90. Following the transaction, the chief executive officer now owns 379,534 shares of the company's stock, valued at approximately $26,635,696.12. This trade represents a 7.73 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 33,055 shares of Insmed stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the sale, the insider now directly owns 138,053 shares of the company's stock, valued at approximately $11,168,487.70. This trade represents a 19.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 496,772 shares of company stock valued at $39,374,121 in the last three months. Corporate insiders own 4.60% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on INSM. Truist Financial upped their price target on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a report on Friday, February 21st. Stifel Nicolaus decreased their target price on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Insmed in a research note on Wednesday, February 19th. Finally, UBS Group lifted their target price on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. One research analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Trading Down 1.9 %

NASDAQ INSM traded down $1.32 on Tuesday, hitting $69.71. 244,861 shares of the company were exchanged, compared to its average volume of 2,267,967. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market capitalization of $12.67 billion, a P/E ratio of -12.45 and a beta of 1.07. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company's 50 day moving average price is $75.99 and its 200-day moving average price is $73.64.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.